This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Meridian Bioscience Reports Third Quarter And Nine Months Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2014 Guidance

Stocks in this article: VIVO

Meridian Bioscience, Inc. (NASDAQ: VIVO) today:

  • reported fiscal 2014 third quarter and first nine months net sales of $47.2 million and $142.1 million, respectively, flat and an increase of 2%, respectively, from the same periods of the prior fiscal year;
  • reported third quarter operating income of $13.1 million, a decrease of 16% from the same period of the prior fiscal year;
  • reported nine months operating income of $40.4 million, a decrease of 8% from the same period of the prior fiscal year;
  • reported third quarter net earnings of $8.8 million, or $0.21 per diluted share, decreases of 13% compared to the fiscal 2013 third quarter;
  • reported first nine months net earnings of $26.6 million, or $0.63 per diluted share, decreases of 8% and 9%, respectively, compared to the same period of fiscal 2013;
  • declared the regular quarterly cash dividend of $0.20 per share for the third quarter of fiscal 2014 (annual indicated rate of $0.80 per share), a 5% increase over the regular quarterly rate for fiscal 2013; and
  • reaffirmed its current fiscal 2014 guidance of per share diluted earnings to between $0.85 and $0.90 on net sales of $190 million to $195 million.

FINANCIAL HIGHLIGHTS (UNAUDITED) In Thousands, Except per Share Data

       

Three Months Ended June 30,

    Nine Months Ended June 30,
2014   2013   % Change 2014   2013   % Change
Net Sales $ 47,212 $ 47,108 - % $ 142,140 $ 139,724 2 %
Operating Income 13,132 15,699 -16 % 40,424 44,043 -8 %
Net Earnings 8,835 10,159 -13 % 26,561 28,882 -8 %
Diluted Earnings per Share $ 0.21 $ 0.24 -13 % $ 0.63 $ 0.69 -9 %
 
June 30,
2014 2013
Cash and Equivalents $ 39,285 $ 40,363
Working Capital 96,507 88,875
Shareholders’ Equity 161,820 151,266
Total Assets 178,763 170,991
 

COMPANY COMMENTS

John A. Kraeutler, Chief Executive Officer, said, “The third fiscal quarter was in-line with our most recently updated guidance, and reflects the increasing complexity of the market, and an expanding competitive climate. Our strategic growth drivers were mixed in their contributions with the more significant increases coming from our illumi gene ® molecular products, +9%, our H. pylori category, +9%, and the Bioline molecular components business growing by 6%. Our new illumi gene Pertussis test contributed $227,000 of revenue for the quarter and is now in use by approximately 80 customers in its first 90 days post-launch. During the quarter we added 30 new illumi gene customers and a total of 94 new assays were installed on both new and existing systems. Despite these highlights, our legacy C. difficile products continued to decline gradually; new competition in the foodborne category, somewhat exacerbated by purchasing patterns, resulted in a 5% quarter over quarter decline; and our core Life Science business faced a difficult year ago comparison.

“Tactically, R&D will continue to focus upon our illumi gene molecular technology platform and the expansion of its menu to include HSV I & II and gonorrhea/chlamydia which are expected to launch in the first half of FY 2015. In addition, we are evaluating multiple new technologies, both molecular and non-molecular, that can expand our menu of infectious disease tests while adding greater workflow simplicity. Going forward we will continue investing in the global expansion of our Life Science business which has already yielded material opportunities in China and surrounding markets.”

William J. Motto, Executive Chairman, stated, “We are very pleased that Dee Ellingwood has joined Meridian's Board of Directors. At Cincinnati Children's Hospital Medical Center since 1997, Mr. Ellingwood previously served as Senior Vice President of Planning and Business Development, developing institutional strategy and leading organizational initiatives to pursue the institution's vision to be the leader in improving child health. Previously, Mr. Ellingwood served as the Vice President of Network Development, Planning and Managed Care for Spohn Health System, a Catholic-based integrated health system in Corpus Christi, Texas. As a loaned executive from Cincinnati Children's Hospital Medical Center, he is leading the Collective Impact on Health planning and processes to establish community backbone functions and drive the initiative toward achieving the Triple Aim of better health, better care and lower costs. We welcome Mr. Ellingwood to our Board and look forward to his contributions.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs